|
|
|
|
|
Inactive Indication- |
Drug Highest PhaseIND Approval |
First Approval Ctry. / Loc.- |
First Approval Date- |
Target- |
MechanismImmunomodulators |
Active Org.- |
|
Active Indication- |
|
Drug Highest PhaseDiscontinued |
First Approval Ctry. / Loc.- |
First Approval Date- |
A Randomized, Double-blind, Placebo-controlled Phase II Exploratory Clinical Trial to Evaluate the Efficacy and Safety of Human COVID-19 Immunoglobulin (pH4) for Intravenous Injection (COVID-HIG) in the Treatment of Patients With COVID-19
A randomized, double-blind, placebo-controlled phase II exploratory clinical trial to evaluate the efficacy and safety of Human COVID-19 immunoglobulin (pH4) for intravenous injection (COVID-HIG) in the treatment of patients with COVID-19.
100 Clinical Results associated with Sinopharm Group Wuhan Blood Products Co. Ltd.
0 Patents (Medical) associated with Sinopharm Group Wuhan Blood Products Co. Ltd.
100 Deals associated with Sinopharm Group Wuhan Blood Products Co. Ltd.
100 Translational Medicine associated with Sinopharm Group Wuhan Blood Products Co. Ltd.